Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab

被引:7
作者
Chan, A. [1 ]
McGregor, S. R. [1 ]
机构
[1] Mt Hosp, Perth, WA, Australia
关键词
HER2; neu; breast cancer; trastuzumab; MONOCLONAL-ANTIBODY; HER-2/NEU GENE; CHEMOTHERAPY; THERAPY; HER2; CYCLOPHOSPHAMIDE; AMPLIFICATION; PROGNOSIS; PLUS;
D O I
10.1111/j.1445-5994.2011.02432.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To ascertain the prevalence of HER2/neu-positive early breast cancer (EBC), utilisation of adjuvant trastuzumab and incidence of cardiac toxicity in a community private hospital setting. Methods: Prospective data collected by breast oncologist and surgeons in all women diagnosed with EBC at the Mount Hospital (MH) were reviewed. Women with HER2/ neu-positive disease diagnosed between 1 October 2006 and 31 March 2009 were included in this analysis. Results: In total, 1128 women with invasive EBC were seen in the 30-month period. All tumours underwent HER2/neu testing by immunohistochemistry, with 61% being evaluated by in situ hybridisation. Time to definitive HER2/neu result improved over time from median of 17 to 14 days. The prevalence of HER2 positivity (by in situ hybridisation) in this cohort was 12%. Uptake of trastuzumab-based treatment was 100% in those patients receiving their treatment at the MH, compared to 52% of the 25 patients treated elsewhere. Ninety-eight per cent of MH patients completed the planned 12 months of therapy, with one patient developing recurrent disease and two patients experiencing significant cardiac toxicity. Chemotherapy relative dose intensity was 98% in HER2/neu-positive and negative patients. At a median of 25 months follow up, actuarial disease-free and overall survival in the HER2/neu-positive cohort is 99% and 100% respectively. Conclusion: In a community private hospital setting, adjuvant trastuzumab and chemotherapy was delivered optimally, in line with national and international guidelines. Early efficacy and safety results in a non-clinical trial setting underscore the significant benefits achieved with this targeted therapy in HER2/neu-positive EBC.
引用
收藏
页码:267 / 274
页数:8
相关论文
共 24 条
[1]   HER2 Testing and Subsequent Trastuzumab Treatment for Breast Cancer in a Managed Care Environment [J].
Barron, John J. ;
Cziraky, Mark J. ;
Weisman, Thomas ;
Hicks, David G. .
ONCOLOGIST, 2009, 14 (08) :760-768
[2]   Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study [J].
Bilous, M ;
Ades, C ;
Armes, J ;
Bishop, J ;
Brown, R ;
Cooke, B ;
Cummings, M ;
Farshid, G ;
Field, A ;
Morey, A ;
McKenzie, P ;
Raymond, W ;
Robbins, P ;
Tan, L .
BREAST, 2003, 12 (02) :92-98
[3]   CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE-POSITIVE BREAST-CANCER - THE RESULTS OF 20 YEARS OF FOLLOW-UP [J].
BONADONNA, G ;
VALAGUSSA, P ;
MOLITERNI, A ;
ZAMBETTI, M ;
BRAMBILLA, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) :901-906
[4]  
Canney P, 2009, J CLIN ONCOL, V27
[5]  
Carlson R, 2010, NAT COMPR CANC NETW, V1
[6]  
Chirgwin J, 2007, HERG RECOMMENDATIONS
[7]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[8]   PROGNOSTIC IMPORTANCE OF C-ERBB-2 EXPRESSION IN BREAST-CANCER [J].
GUSTERSON, BA ;
GELBER, RD ;
GOLDHIRSCH, A ;
PRICE, KN ;
SAVESODERBORGH, J ;
ANBAZHAGAN, R ;
STYLES, J ;
RUDENSTAM, CM ;
GOLOUH, R ;
REED, R ;
MARTINEZTELLO, F ;
TILTMAN, A ;
TORHORST, J ;
GRIGOLATO, P ;
BETTELHEIM, R ;
NEVILLE, AM ;
BURKI, K ;
CASTIGLIONE, M ;
COLLINS, J ;
LINDTNER, J ;
SENN, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1049-1056
[9]   ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy [J].
Kouloubinis, Alexandros ;
Kaklamanis, Loukas ;
Ziras, Nikolaos ;
Sofroniadou, Sofia ;
Makaritsis, Konstantinos ;
Adamopoulos, Stamatios ;
Revela, Ioanna ;
Athanasiou, Athanasios ;
Mavroudis, Dimitrios ;
Georgoulias, Vasillios .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 122 (03) :195-201
[10]  
Letarte N, 2008, J CLIN ONCOL S, V26, P6615